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Interleukin-1b Attenuates Myofibroblast Formation and
Extracellular Matrix Production in Dermal and Lung
Fibroblasts Exposed to Transforming Growth Factor-b1
Masum M. Mia, Miriam Boersema, Ruud A. Bank*
Division of Medical Biology, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands,
Abstract
One of the most potent pro-fibrotic cytokines is transforming growth factor (TGFb). TGFb is involved in the activation of
fibroblasts into myofibroblasts, resulting in the hallmark of fibrosis: the pathological accumulation of collagen. Interleukin-
1b (IL1b) can influence the severity of fibrosis, however much less is known about the direct effects on fibroblasts. Using
lung and dermal fibroblasts, we have investigated the effects of IL1b, TGFb1, and IL1b in combination with TGFb1 on
myofibroblast formation, collagen synthesis and collagen modification (including prolyl hydroxylase, lysyl hydroxylase and
lysyl oxidase), and matrix metalloproteinases (MMPs). We found that IL1b alone has no obvious pro-fibrotic effect on
fibroblasts. However, IL1b is able to inhibit the TGFb1-induced myofibroblast formation as well as collagen synthesis.
Glioma-associated oncogene homolog 1 (GLI1), the Hedgehog transcription factor that is involved in the transformation of
fibroblasts into myofibroblasts is upregulated by TGFb1. The addition of IL1b reduced the expression of GLI1 and thereby
also indirectly inhibits myofibroblast formation. Other potentially anti-fibrotic effects of IL1b that were observed are the
increased levels of MMP1, 22, 29 and 214 produced by fibroblasts exposed to TGFb1/IL1b in comparison with fibroblasts
exposed to TGFb1 alone. In addition, IL1b decreased the TGFb1-induced upregulation of lysyl oxidase, an enzyme involved
in collagen cross-linking. Furthermore, we found that lung and dermal fibroblasts do not always behave identically towards
IL1b. Suppression of COL1A1 by IL1b in the presence of TGFb1 is more pronounced in lung fibroblasts compared to dermal
fibroblasts, whereas a higher upregulation of MMP1 is seen in dermal fibroblasts. The role of IL1b in fibrosis should be
reconsidered, and the differences in phenotypical properties of fibroblasts derived from different organs should be taken
into account in future anti-fibrotic treatment regimes.
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Introduction
Fibrosis is the result of defective repair processes often seen after
chronic injury and/or inflammation in a large variety of organs
and tissues, such as the kidney, heart, liver, lung and skin. IL1b has
been implicated as one of the dominant players in the
development of fibrosis [1,2,3,4,5,6,7]. Like various organ fibrosis,
lung and skin fibrosis are mediated by the IL1b [6,7,8]. It is
expressed in the acute phase of inflammation, but is also elevated
in the later stages of inflammation and tissue repair. The hallmark
of fibrosis is an excessive accumulation of extracellular matrix
(ECM), especially due to an imbalance between collagen synthesis
and degradation [8,9,10,11,12]. One of the key processes in
fibrosis is the activation of fibroblasts into myofibroblasts [13], a
process that seems to be dependent on the activation of the GLI1
of the Hedgehog pathway [12,14]. The consensus is that
myofibroblasts are ultimately responsible for the excessive
deposition of ECM in fibrosis.
Various cytokines play a role in the differentiation of fibroblasts
into myofibroblasts. One of the major pro-fibrotic cytokines is
transforming growth factor-b (such as TGFb1), as it induces the
differentiation of fibroblasts into myofibroblasts. Myofibroblasts
are characterized by the presence of cytoplasmic stress fibers and
show an excessive production of collagen [9,15,16,17,18,19,20].
TGFb1 is also involved in the disbalance regarding the expression
of matrix metalloproteinases capable of degrading collagen (e.g.
MMP1, 22, 29 and 214) versus their inhibitors (e.g. tissue
inhibitor of matrix metalloproteinase 1 and 22) [21].
As mentioned, IL1b influences the severity of fibrosis. Neutral-
isation or other ways of knocking down of IL1b in vivo results in an
attenuation of fibrosis [1,2,3,4,5], whereas increasing the level of
IL1b enhances the severity of fibrosis [2,6,7]. However, the direct
effect of IL1b on fibroblasts is unclear. It has been known for a
long time that fibroblasts exposed to IL1b invariably increase the
expression of a variety of MMPs, and subsequently the breakdown
of collagen [22,23,24,25,26,27,28]. This anti-fibrotic phenomenon
shows a dual role for IL1b in fibrosis, as this should diminish the
excessive accumulation of ECM. Conflicting data exists regarding
the direct effect of IL1b on fibroblasts with respect to collagen
expression/synthesis. Elevated levels of collagen expression/
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synthesis have been reported [29,30,31], but also opposite data
[22,26,27], or no changes at all have been published [32,33,34].
We are not aware of studies regarding the effects of IL1b on the
differentiation of fibroblasts to myofibroblasts, although a number
of studies show that IL1b is able to induce epithelial to
mesenchymal transition (EMT) and endothial to mesenchymal
transition (EndoMT), i.e. the formation of myofibroblasts out of
epithelial and endothelial cells [10,35,36]. Furthermore, not much
is known whether IL1b and TGFb1 have co-stimulatory effects,
although both cytokines are present during tissue repair processes.
Interestingly, about two decades ago it has been reported that
IL1b is able to inhibit collagen type I synthesis in fibroblasts that
are exposed to TGFb [32], but this potentially anti-fibrotic finding
seems to be overlooked.
In this study we investigated the effects of IL1b, TGFb1, and a
combination of IL1b and TGFb on cultured adult human dermal
and lung fibroblasts (HDFa and HLFa, respectively). The
following questions were addressed: is IL1b (with or without the
presence of TGFb1) involved in (1) fibroblast to myofibroblast
differentiation (including the activation of the Hedgehog pathway),
(2) collagen synthesis (including the collagen-modifying enzymes
prolyl hydroxylase, lysyl hydroxylase, and lysyl oxidase), and (3)
increased levels of MMPs. In addition, we investigated whether
fibroblasts derived from different organs (lung, skin) respond
equally to pro-fibrotic stimuli. The rationale for this is that
fibroblasts from internal organs show dramatic differences in gene
expression patterns compared to dermal fibroblasts [37,38].
Materials and Methods
Cell culture
HDFa [CCD-1093Sk (ATCC CRL-2115), ATCC, USA] and
HLFa [CCD-19Lu (ATCC CCL-210), ATCC, USA] were
cultured in Eagle’s minimal essential medium (EMEM) (BE12-
662F, Lonza Group Ltd, Switzerland) supplemented with 1% L-
glutamine (Lonza, Switzerland), 1% penicillin/streptomycin
(Gibco Life Technologies Ltd., UK) and 10% fetal bovine serum
(FBS) (Thermo Scientific, USA) at 37uC in 5% CO2. Passage 7 to
12 of HDFa and HLFa were seeded with a density of 15,000 cells/
cm2 onto a Costar 12-well plate (for quantitative real time
polymerase chain reaction) or a 24-well plate (Corning Inc., USA)
(for immunofluorescence staining). Cells were washed with
phosphate buffer saline (PBS) after 72 h and starved for 16 h in
EMEM supplemented with 1% L-glutamine, 1% penicillin/
streptomycin and 0.5% FBS. Cultures were then stimulated
with/without recombinant human IL1b (10 ng/ml) (201-LB-005,
R&D Systems Inc, USA), recombinant human TGFb1 (0.5, 2 and
10 ng/ml) (100–21, Peprotech, UK), or combinations thereof, for
the time period as indicated. Subsequently, whole-cell lysates (as
obtained with RLT-buffer; Qiagen Inc, USA), cells fixed by 1%
para-formaldehyde (PFA; Merck, Germany), or collected condi-
tioned media were used for quantitative real time polymerase
chain reaction (qRT-PCR), immunofluorescence staining, and
LOX activity tests, respectively.
RNA isolation, cDNA synthesis and qRT-PCR
HDFa and HLFa were treated with IL1b and/or TGFb1 for
24 h (or 48 h) or pre-treated with TGFb1 (48 h) followed by IL1b
stimulation for 48 h. Total RNA was isolated using the RNeasy
Kit (Qiagen Inc., USA) according to the manufacturer’s protocol.
RNA concentration and RNA quality were measured with UV
spectrophotometry (NanoDrop Technologies, Wilmington, NC).
For the synthesis of cDNA, total RNA was reverse transcribed with
the First Strand cDNA synthesis kit (Fermentas UAB, Lithuania)
according to the manufacturer’s protocol. Gene expression
analysis was performed by means of qRT-PCR in a 10 ml reaction
mixture containing 10 ng cDNA, SYBR Green Supermix (Bio-
Rad, USA), 6 mM forward primer, and 6 mM reverse primer (for
primer sequences see Table 1). qRT-CPR was performed in
triplicate for each condition in a 384-well plate at 95uC for 15 sec
and 60uC for 1 min for 40 cycles using the ViiA 7 Real-Time PCR
System (Applied Biosystems, USA). Data was analysed with the
ViiA 7 Real-Time PCR System Software v1.1 (Applied Biosys-
tems, USA).
Immunofluorescence staining for aSMA and SM22a
HDFa and HLFa were cultured in 24-well plates and treated for
48 h with (1) IL1b, (2) TGFb1, or (3) a combination of both. In
another experiment, fibroblasts were pre-treated with TGFb1
(48 h) followed by IL1b stimulation for 48 h. After treatment, cells
were washed with PBS and fixed with 1% PFA in PBS for 15 min
at room temperature (RT). Cells were then permeabilized with
0.5% Triton X-100 (Merck, Germany) in PBS for 3 min at RT.
Subsequently, cells were washed and incubated for 1 h at RT with
(1) monoclonal mouse anti-human to aSMA (M0851, Dako,
Denmark) or (2) polyclonal rabbit to SM22a (ab14106, Abcam,
UK); both primary antibodies were diluted 1:100 in PBS
containing 2% bovine serum albumin (BSA) (K1106, Sanquin
reagents, Netherlands). After washing with PBS, cells were
incubated for 30 min at RT with biotinylated secondary antibody
(1) goat-anti-mouse (1080-08, SouthernBiotech, USA) (1:100) or
(2) goat anti-rabbit (E0432, Dako, Denmark) (1:100) diluted in
PBS containing 2% BSA for 30 min at RT. The cells were washed
again and incubated with streptavidine-CY3 (Invitrogen, USA)
(1:100) in PBS containing 1% BSA and DAPI (1:10,000) for
30 min. After washing with PBS, cell culture wells were mounted
with citifluor (Agar Scientific, UK) and analyzed by fluorescence
imaging microscopy (TissueFAXS, TissueGnostics GmbH, Aus-
tria), which is a valid method of quantification of immunofluores-
cent staining. Briefly, immunofluorescence staining was performed
in a 24-well culture plate. The total area of the well was scanned
Table 1. List of primers used for qRT-PCR analysis.
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Figure 1. Effects of IL1b on TGFb1-induced aSMA synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1b, TGFb1,
or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as fold
change compared to untreated control. (C) Representative immunofluorescence stainings for aSMA are shown for HDFa (upper panel) and HLFa
(lower panel). White scale bar represents 100 mm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for aSMA
positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for aSMA are shown for HDFa and HLFa respectively.
doi:10.1371/journal.pone.0091559.g001
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Figure 2. Post-treatment effects of IL1b on TGFb1-induced aSMA synthesis in dermal and lung fibroblasts. Fibroblasts were pre-treated
with TGFb1 for 48 h followed by IL1b for 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as
fold change compared to untreated control. (C) Representative immunofluorescence stainings for aSMA are shown for HDFa (upper panel) and HLFa
(lower panel). White scale bar represents 100 mm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for aSMA
positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for aSMA are shown for HDFa and HLFa respectively.
doi:10.1371/journal.pone.0091559.g002
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Figure 3. Effects of IL1b on TGFb1-induced SM22a synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1b,
TGFb1, or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and expressed as
fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22a are shown for HDFa (upper panel) and HLFa
(lower panel). White scale bar represents 100 mm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for SM22a
positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22a are shown for HDFa and HLFa respectively.
doi:10.1371/journal.pone.0091559.g003
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Figure 4. Post-treatment effects of IL1b on TGFb1-induced SM22a synthesis in dermal and lung fibroblasts. Fibroblasts were pre-
treated with TGFb1 for 48 h followed by IL1b for 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and
expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22a are shown for HDFa (upper
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by the TissueFAXS after which we used the TissueQuest software
to quantify the total number of nuclei and the number of nuclei
positive for the protein visualized in that particular experiment.
The TissueQuest quantification results in scattergram. Each dot in
a scattergram represent a nucleus and the fluorescent intensity as a
measure for the amount of protein present of that particular cell
can be determined on the Y-axis. Data are presented as a
percentage of positive cells (mean 6 SEM) of four to six
independent experiments.
Collagen type I staining
HDFa and HLFa were treated for 7 days with (1) IL1b, (2)
TGFb1, or (3) both. Additionally, Vitamin C (Sigma-Aldrich,
USA) was added to the cell culture media. For collagen type I
detection, we followed the same protocol as described above to
detect aSMA and SM22a. To observe the production of
intracellular and extracellular collagen, stainings were performed
with or without Triton x-100 (Merck, Germany) permeabilization.
Monoclonal mouse to collagen type I (1:100) (ab90395, Abcam,
UK) was used as primary antibody, and a biotinylated goat-anti-
mouse (1:100) as secondary antibody (SouthernBiotech, USA).
Collagen type I immunofluorescence was visualized using
TissueFAXS as described above.
LOX activity assay
To measure the activity of LOX, conditioned media of
fibroblasts treated for 24 and 48 h with (1) IL1b, (2) TGFb1, or
(3) both were used. LOX activity was determined with the Amplite
Fluorimetric Lysyl Oxidase Assay Kit (AAT Bioquest Inc, USA) in
accordance to the manufacturer’s protocol. Briefly, 50 ml of assay
reaction mixture was prepared, followed by the addition of 50 ml
of conditioned media. The mixture was incubated at 37uC for
20 min; fluorescence intensity was detected at Excitation/Emis-
sion 540/590 nm with a Varioskan Flash Multimode Reader.
Background fluorescence was subtracted and the conditioned
media values were calculated and expressed as relative fluores-
cence intensity (RFU). To present the LOX activity, value of each
treatment were plotted as bar graph. Data are presented as mean
6 SEM for two independent experiments. The whole reaction was
performed in a black 96-well plate.
Statistics
All mRNA data were normalized against the reference gene
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activa-
tion protein, zeta polypeptide (YWHAZ). Data are presented as
mean 6 SEM for at least three independent experiments. All
immunofluorescence data are presented as mean 6 SEM for at
least four independent experiments. Results were analysed either
with a one-way analysis of variance (ANOVA) followed by Tukey’s
post-test analysis or two-way ANOVA followed by Bonferroni
post-test analysis using Graph-Pad Prism Version 5 (GraphPad
Software Inc., USA). P,0.05 was considered to be statistically
significant. *** P,0.001, ** P,0.01, * P,0.05.
Results
Dose-dependent effect of cytokines
To investigate the optimal concentration of TGFb1, we
performed a dose-dependent titration experiment with three
concentrations of TGFb1 (0.5, 2 and 10 ng/ml) in combination
with 10 ng/ml of IL1b for 48 hours on both dermal and lung
fibroblasts. Gene expression analysis showed that stimulation of
fibroblasts with 0.5 ng of TGFb1 did not increase the expression
of ACTA2 in HDFa (Fig. S1A). However, 0.5 ng of TGFb1 was
sufficient to significantly increase the expression of ACTA2 in
HLFa (Fig. S1B). A higher dose of TGFb1 (2 ng/ml) did increase
the expression of ACTA2 in both types of fibroblasts (Fig. S1A–B),
as well as that of other genes (GLI1, COL1A1, PLOD2) that are
associated with the differentiation of fibroblasts into myofibroblasts
(Fig. S1C–F and S2A–B). However, both in HDFa and HLFa, the
increase in gene expression levels as a result of stimulation with
2 ng/ml of TGFb1 often did not reach the levels of the
experiments with 10 ng/ml TGFb1 (for example Fig. 1A–B).
In the titration experiment, IL1b did not reduce the expression
of ACTA2 in HLFa (Fig. S1B) and GLI1 in HDFa (Fig. S1C)
when fibroblasts were treated with either 0.5 or 2 ng/ml of
TGFb1, although this was seen for 10 ng/ml (for example Fig. 1A–
B). However, IL1b was able to downregulate the TGFb1-induced
COL1A1 gene expression on both types of fibroblast (Fig. S1E–F).
We did find a dose-dependent effect of TGFb1 on the gene
expression levels of MMP1 (Fig. S2C–D).
These findings suggest that a lower dose of TGFb1 was
sufficient to increase the gene expression of several genes
associated with myofibroblast differentiation and matrix remod-
elling. However, the increase in gene expression after stimulation
with 0.5 and 2 ng/ml of TGFb1 was quite limited for some genes.
Therefore, throughout this paper, we describe the findings of the
effects of 10 ng/ml TGFb1 and IL1b.
IL1b inhibits TGFb1-induced aSMA synthesis
TGFb1 is the principal cytokine involved in the transition of
fibroblasts into myofibroblasts [15,39]. Myofibroblasts show, in
contrast to fibroblasts, extensive cytoplasmic stress fibers with
alpha smooth muscle actin (aSMA) and smooth muscle protein 22-
alpha (SM22a) as its components [40,41,42]. In order to examine
the effect of IL1b on TGFb1-induced aSMA expression,
fibroblasts were treated either with IL1b, TGFb1, or both for 24
or 48 h (Fig. 1A–F). In addition, cells were pre-treated with
TGFb1 for 48 h followed by incubation with IL1b for 48 h
(Fig. 2A–F). The results showed that IL1b alone did not have an
effect on smooth muscle actin alpha 2 (ACTA2) mRNA expression
compared to untreated cells (Fig. 1A–B). However, ACTA2
expression was significantly increased in TGFb1-stimulated cells
over time, and ACTA2 gene expression was significantly
decreased when the two cytokines were combined in HDFa and
HLFa at both time points (Fig. 1A–B). Even post-treatment with
IL1b significantly decreased the TGFb1-induced ACTA2 gene
expression (Fig. 2A–B). To confirm the mRNA expression data on
protein level, changes in cytoskeleton structure of fibroblasts and
myofibroblasts were investigated by immunofluorescence staining
for aSMA. In line with the mRNA data, IL1b alone had no effect
on actin stress fiber formation in quiescent HDFa and HLFa, and
stimulation with TGFb1 resulted in the formation of actin stress
fibers in both cell types (Fig. 1C–F). Furthermore, in a TGFb1-rich
environment, IL1b counteracted the TGFb1-induced actin stress
fiber formation, both in a combined (Fig. 1C–F) and in a post-
treatment fashion in both HLFa and HDFa (Fig. 2C–F). Thus,
from the aSMA data we conclude that IL1b is able to diminish
TGFb1-induced myofibroblast formation.
panel) and HLFa (lower panel). White scale bar represents 100 mm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right
corner) for SM22a positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22a are shown for HDFa and HLFa respectively.
doi:10.1371/journal.pone.0091559.g004
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Figure 5. Effects of IL1b on TGFb1-induced gene expression of Hedgehog pathway effector GLI1 and its isoform GLI1DN in dermal
and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1b, TGFb, or a combination of both for 24 and 48 h. The mRNA levels of GLI1 were
measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) The mRNA level of GLI1 in HDFa and HLFa. Fibroblasts
were pre-treated with TGFb1 for 48 h followed by IL1b for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated
control. (E–F) HDFa and HLFa were treated with IL1b, TGFb1, or a combination of both, for 24 and 48 h. The mRNA levels of GLI1DN were measured
with qRT-PCR and expressed as fold change compared to untreated control. (G–H) The mRNA level of GLI1DN in HDFa and HLFa. Fibroblasts were
pre-treated with TGFb1 for 48 h followed by IL1b for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
doi:10.1371/journal.pone.0091559.g005
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IL1b inhibits TGFb1-induced SM22a synthesis
Although aSMA is the most prominent marker of myofibro-
blasts, these cells are also characterized by elevated levels of
SM22a, which is an actin isoform. We therefore evaluated
whether IL1b has similar effects on SM22a. Fibroblasts treated
with IL1b already showed a trend of decreasing transgelin
(TAGLN) mRNA levels in quiescent HLFa (Fig. 3B). As expected,
an upregulation of TAGLN was seen in TGFb1-treated cells. As
observed with ACTA2, treatment with a combination of IL1b and
TGFb1 caused a significant downregulation of TAGLN gene
expression in HDFa after 24 h and in HLFa after 24 h or 48 h
(Fig. 3A–B), although no downregulation was seen for HDFa at
48 h. Immunofluorescence studies showed that untreated fibro-
blasts are SM22a positive, however upon IL1b stimulation the
intensity of SM22a staining decreased (Fig. 3C–F). TGFb1
stimulation highly increased the SM22a staining in HDFa and
HLFa, which was significantly inhibited in HDFa in the presence
of IL1b (Fig. 3C–F). Post-treatment with IL1b for 48 h
significantly reduced the TGFb1-induced upregulation of TAGLN
mRNA expression in HLFa (Fig. 4B), but not in HDFa (Fig. 4A).
The protein analysis revealed that post-treatment with IL1b
reversed the TGFb1-induced SM22a protein levels both in HDFa
and HLFa (Fig. 4C–F). Thus, also the SM22a data shows that
IL1b is able to diminish the TGFb1-induced myofibroblast
formation.
IL1b reduces TGFb1-induced GLI1 and GLI1DN gene
expression
Given the fact that GLI1 is required for the differentiation of
fibroblasts into myofibroblasts [12,14,43], we tested whether the
attenuation by IL1b of TGFb1-induced activation of fibroblasts is
indeed paralleled by decreased levels of GLI1. HDFa and HLFa
were exposed to IL1b, TGFb1, or both, for 24 h and 48 h
(Fig. 5A–B). No differences were detected in GLI1 mRNA levels
between IL1b-stimulated and untreated fibroblasts at both time
points. GLI1 mRNA levels were significantly increased (,10-fold
in HDFa and ,3-fold in HLFa) after TGFb1 treatment (Fig. 5A–
B). Interestingly, incubation with a combination of IL1b and
TGFb1 significantly reduced the mRNA expression of GLI1 in
HDFa compared to TGFb1 alone (Fig. 5A), whereas IL1b only
significantly suppressed GLI1 expression at 48 h in HLFa (Fig. 5B),
although a trend was seen at 24 h. HLFa treated with TGFb1 for
48 followed by IL1b stimulation for 48 h showed a significant
reduction in expression of GLI1; while only a trend was seen for
HDFa (Fig. 5C–D). Thus, inhibition of myofibroblast differenti-
ation by IL1b is partially reflected in decreased GLI1 levels.
Recently, an isoform of GLI1, named GLI1DN, has been
identified [44]. However, there is limited evidence about its
expression and function in fibroblasts and myofibroblasts. We
asked whether GLI1DN also respond to IL1b- and TGFb1-treated
fibroblasts. As was the case with GLI1, the GLI1DN mRNA level
was not affected after IL1b treatment, and was significantly
upregulated up to ,6-fold in HDFa and up to ,3-fold in HLFa
after TGFb1 stimulation (Fig. 5E–F). Treatment of fibroblasts with
IL1b and TGFb1 together significantly decreased the expression
of GLI1DN at 48 h compared to TGFb1 alone (Fig. 5E–F). This
was also observed when fibroblasts were treated first with TGFb1
for 48 h, and treated afterwards for 48 h with IL1b (Fig. 5G–H),
although a significance was only reached for HLFa. These findings
suggest that in a pro-fibrotic environment the response of GLI1DN
to cytokine IL1b is similar to that of GLI1.
IL1b decreases TGFb1-induced collagen type I synthesis,
while it increases the expression of COL3A1
Under fibrogenic conditions, myofibroblasts are responsible for
the production of excessive ECM. TGFb1 has been reported to
induce accumulation of collagen type I [19,45,46,47]. As we have
shown above, IL1b reversed the TGFb1-induced aSMA and
SM22a expression. However, the presence of aSMA or SM22a is
not required for myofibroblasts to deposit ECM. We therefore
investigated whether IL1b is also able to reduce the production of
ECM molecules, such as collagen, in a TGFb-rich pro-fibrotic
environment. Compared to untreated fibroblasts, IL1b did not
alter mRNA levels of collagen type I alpha 1 (COL1A1), whereas
TGFb1 upregulated COL1A1 up to ,5- to 7-fold in HDFa
(Fig. 6A) and ,2- to 4-fold in HLFa (Fig. 6B) at 24 h to 48 h,
respectively. A considerable reduction of COL1A1 expression was
detected at 48 h when cells were treated with a combination of
TGFb1 and IL1b (Fig. 6A–B). As expected from the mRNA data,
a collagen type I staining by means of immunofluorescence
revealed a strong expression both intracellular (Fig. 6C–F) and
extracellular (Fig. 7A–D) in either type of fibroblasts treated with
TGFb1 alone. A considerable reduction of collagen type I staining
was seen when cells were co-stimulated with IL1b (Fig. 6C and
7A). Quantification of the % of cells stained positive for
intracellular collagen after 7 days demonstrated that IL1b alone
had no effect, that TGFb1 notably induced collagen synthesis, and
that the combination of TGFb1 with IL1b showed a clear trend of
decreasing collagen type I synthesis in both HDFa and HLFa
(Fig. 6D–F). On the other hand, quantification of the % of cells
positive for extracellular deposited, collagen type I after 7 days
revealed that IL1b almost completely abolished the TGFb1-
induced collagen type I production in HLFa, whereas a trend was
seen for HDFa (Fig. 7A–D).
Post-treatment with IL1b also significantly decreased the
mRNA level of COL1A1 in HLFa pre-treated with TGFb1
(Fig. 7F). However, under the same conditions, no such decrease
in COL1A1 mRNA levels was seen in HDFa (Fig. 7E).
Interestingly, an opposite effect was observed for collagen type
III alpha 1 (COL3A1) gene expression. Either IL1b or TGFb1-
treatment significantly increased the mRNA level of COL3A1 in
HDFa at both time points (at 24 and 48 h) (Fig. 8A) and in HLFa
at 48 h of incubation (Fig. 8B). The fold-increase in COL3A1
mRNA levels compared to untreated cells was higher in HDFa
than in HLFa. A combination of the cytokines resulted mRNA
levels of COL3A1 that were the same (in HLFa) or even higher (in
HDFa) compared to fibroblasts that were treated with TGFb1
alone (Fig. 8A–B). This was also observed when fibroblasts were
treated first with TGFb1 for 48 h, and treated afterwards for 48 h
with IL1b (Fig. 8C–D). Thus, co-treatment or post-treatment with
IL1b never resulted in a downregulation in mRNA expression of
COL3A1, which is in contrast to what was seen with COL1A1.
Figure 6. Effects of IL1b on TGFb1-induced collagen type I synthesis in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated
with IL1b, TGFb1, or a combination of both, for 24 and 48 h. The mRNA levels of COL1A1 were measured with qRT-PCR and expressed as fold change
compared to untreated control. (C) Visualisation of synthesized collagen (intracellular) by HDFa (upper panel) and HLFa (lower panel) treated for 7
days with IL1b, TGFb1 and in combination thereof. White scale bar of each image represents 100 mm. (D) Representative TissueFAXS plots showing
the % of positive cells (upper right corner) for intracellular collagen type I in HDFa. (E–F) Quantification of the % of cells positive for intracellular
collagen type I are shown for HDFa and HLFa respectively.
doi:10.1371/journal.pone.0091559.g006
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IL1b and TGFb1 ameliorate P4HA1, P4HB, PLOD1 and
PLOD2 gene expression
In the previous paragraph we showed that IL1b by itself does
not affect COL1A1 expression, whereas TGFb1 increases
COL1A1 expression and that IL1b was able to attenuate the
TGFb1-induced expression of COL1A1. It should be noted that
processing of collagen type I (as well as the other collagen types) is
a complex process as several enzymes are involved in the
processing and modification of collagen. Some of these enzymes
play a key role in the stability of the collagen molecule/fibril. In
fibrosis, an increase in the expression of collagen-modifying
enzymes such as prolyl hydroxylase (e.g. P4H1, P4HB) and lysyl
hydroxylase (e.g. PLOD1 and -2) has been shown in e.g. lung and
skin fibrosis [48,49,50,51]. TGFb1 is able to stimulate the
expression of the mentioned enzymes [52]. However, the effect
of IL1b on the gene expression level of P4HA, P4HB, PLOD1 and
PLOD2 is unknown. We investigated whether IL1b is able to
counteract the TGFb1-induced overexpression of these enzymes,
as we have observed for COL1A1. Gene expression analysis
(Fig. 9A-H) demonstrate that IL1b, like TGFb1, significantly
upregulates the expression of these enzymes in quiescent
fibroblasts both at 48 h, and often also at 24 h (Fig. 9A–H).
Treatment with a combination of IL1b and TGFb1 did not result
in a decrease in expression of the enzymes (which is in contrast
with COL1A1); in fact, mRNA levels remained the same or were
even higher compared to fibroblasts that were treated with TGFb1
alone. The most notable increase in expression was observed of
PLOD2: the expression of this enzyme was synergistically induced
by the combination of IL1b with TGFb1 (Fig. 9G–H). This was
also observed when fibroblasts were treated first with TGFb1 for
48 h, and treated afterwards for 48 h with IL1b (Fig. 9I–J). The
enzyme telopeptide lysyl hydroxylase, which is encoded by
PLOD2, specifically hydroxylates the lysine residues in the
telopeptides, giving rise to the formation of hydroxyallysine-
derived cross-links (such as pyridinoline) at the expense of allysine-
derived cross-links. Pyridinoline cross-links are increased in fibrosis
and seem to be associated with its irreversibility [53,54].
Figure 7. Effects of IL1b on TGFb1-induced production of extracellular collagen type I in dermal and lung fibroblasts. (A) Visualisation
of deposited extracellular collagen by HDFa (upper panel) and HLFa (lower panel) treated for 7 days with IL1b, TGFb1 and in combination thereof.
White scale bar of each image represents 100 mm. (B) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for
extracellular collagen type I in HDFa. (C–D) Quantification of the % of cells surrounded by extracellular collagen type I protein are shown for HDFa
and HLFa respectively. (E–F) Fibroblasts were pre-treated with TGFb1 for 48 h followed by IL1b for 48 h. The mRNA levels of COL1A1 of HDFa and
HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control.
doi:10.1371/journal.pone.0091559.g007
Figure 8. Effects of IL1b and TGFb1 on the expression of collagen type III in dermal and lung fibroblasts. (A–B) HDFa and HLFa were
treated with IL1b, TGFb1, or a combination of both, for 24 and 48 h. The mRNA levels of COL3A1 were measured with qRT-PCR and expressed as fold
change compared to untreated control. (C–D) The mRNA level of COL3A1 in HDFa and HLFa. Fibroblasts were pre-treated with TGFb1 for 48 h
followed by IL1b for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
doi:10.1371/journal.pone.0091559.g008
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IL1b reduces TGFb1-induced LOX mRNA expression and
activity
A basic step in cross-link formation is the formation of aldehydes
by means of lysyl oxidase (LOX). LOX is an extracellular enzyme
involved in the intermolecular cross-linking between collagen
molecules within fibrils, enhancing the stability of the ECM [55].
Increased LOX activity and expression has been found in e.g. skin
and lung fibrosis [56,57,58]. As expected, the expression was
significantly increased in TGFb1-stimulated HDFa and HLFa
(Fig. 10A–B). Interestingly, the presence of IL1b resulted in a
significant down-regulation of the TGFb1-induced expression of
LOX in either type of fibroblasts at 48 h (Fig. 10A–B).
Fluorometric determination of LOX activity in the culture
medium showed a positive correlation with mRNA data
(Fig. 10C–D). Upon stimulation with IL1b, no obvious change
in LOX activity was seen for HDFa and HLFa, whereas activity
was increased in TGFb1-exposed fibroblasts after 48 h. A
combination of IL1b with TGFb1 decreased the LOX activity
in the culture medium of HDFa and HLFa at 48 h (Fig. 10C–D).
IL1b activates expression of the mRNA of MMPs in
TGFb1-enriched fibroblasts
In fibrosis, a disbalance is seen between collagen expression and
the expression of collagenases and gelatinases: the increase in
collagen expression is not accompanied with an increase in MMP
expression. We investigated the effect of IL1b on the expression of
MMP1, 22, 29 and 214 in a non-fibrotic (without TGFb1) and
in a pro-fibrotic (with TGFb1) environment (Fig. 11–12). We
observed that IL1b resulted in a significant upregulation of
MMP1,22 and 214 in a non-fibrotic environment both in HDFa
and HLFa. As expected, TGFb1 alone did not upregulate gene
expression of the measured MMPs. Stimulation of fibroblasts with
IL1b resulted in an upregulation of most MMPs compared to non-
stimulated cells. The increased gene expression of MMPs after
IL1b stimulation was also obvious in the presence of TGFb1
(Fig. 11A–H and Fig. 12A–D). However, TGFb1 did affect the
level of gene expression of certain MMPs in the presence of IL1b.
The increased expression of MMP14 caused by IL1b was
dampened by TGFb1 in HLFa, whereas no such attenuation
Figure 9. Effects of IL1b and TGFb1 on the expression of the intracellular collagen-modifying enzymes prolyl hydroxylase (P4HA1,
P4HB) and lysyl hydroxylase (PLOD1, PLOD2) in dermal and lung fibroblasts. (A–H) HDFa and HLFa were treated with IL1b, TGFb1, or a
combination of both, for 24 and 48 h. The mRNA levels of P4HA1, P4HB, PLOD1 and PLOD2 were measured with qRT-PCR and expressed as fold
change compared to untreated control. (I–J) The mRNA levels of PLOD2 in HDFa and HLFa. Fibroblasts were pre-treated with TGFb1 for 48 h followed
by IL1b for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
doi:10.1371/journal.pone.0091559.g009
Figure 10. Effects of IL1b and TGFb1 on the expression and activity level of lysyl oxidase in dermal and lung fibroblasts. (A–B) HDFa
and HLFa were treated with IL1b, TGFb1, or a combination of both, for 24 and 48 h. The mRNA levels of LOX were measured with qRT-PCR and
expressed as fold change compared to untreated control. (C–D) Quantification of lysyl oxidase activity as secreted in the culture medium by HDFa
and HLFa treated with IL1b, TGFb1, or a combination of both for 24 and 48 h.
doi:10.1371/journal.pone.0091559.g010
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was seen in HDFa (Fig. 11G–H). In contrast, the increased MMP9
levels caused by IL1b were even further upregulated in the
presence of TGFb1 (Fig. 11E–F). Fibroblasts treated with TGFb1
for 48 h followed by IL1b treatment for 48 h showed a high
upregulation of MMP9 (Fig. 12A–B). Such an upregulation was
also observed for MMP1 in HDFa, whereas a pre-treatment with
TGFb1 resulted in a dampening of MMP1 expression in HLFa
(Fig. 12C–D).
Discussion
It has been reported, that IL1b has a deleterious role in fibrosis
in vivo. However, in these studies the role of IL1b in the different
phases of fibrosis, i.e. the acute inflammation phase and the later
stages of inflammation and tissue repair, has not been dissected.
Furthermore, relatively little is known about the direct effects of
IL1b on fibroblasts, and even less is known whether IL1b
influences the pro-fibrotic effect of TGFb1 towards fibroblasts. We
have investigated the direct role of IL1b on dermal and lung
fibroblasts, in the presence or absence of TGFb1, and found that
IL1b alone did not contribute to the formation of myofibroblasts,
and that IL1b on the contrary is able to attenuate or even reverse
the pro-fibrotic effects of TGFb1.
Although IL1b alone did show a stimulatory effect on the
expression of COL3A1 and the collagen-modifying enzymes
P4HA1, P4HB, PLOD1 and PLOD2, we observed that IL1b
alone had no stimulatory effect of GLI1, GLI1DN, COL1A1,
ACTA2 and TAGLN mRNA expression levels (i.e. it did not
contribute to the activation of fibroblasts into myofibroblasts or to
the increase in collagen type I expression). Furthermore, IL1b
alone did have a stimulatory effect on the expression of
collagenolytic enzymes MMP1, 22, 29 and 214, which is
another potentially positive (i.e. anti-fibrotic) effect. A major
finding of our study is further, that the co-presence of IL1b
inhibited the pro-fibrotic stimulatory effects of TGFb1, by
decreasing the mRNA levels of GLI1, GLI1DN, COL1A1,
ACTA2 and TAGLN, an effect that was verified on a protein
level as well. Thus, IL1b inhibits myofibroblast formation as
induced by TGFb1, and therefore potentially could attenuate the
severity of fibrosis. Other potentially positive (i.e. anti-fibrotic)
effects of IL1b were the increased levels of MMP1, 22, 29 and
214 produced by fibroblasts exposed to TGFb1/IL1b compared
to fibroblasts exposed to TGFb1 alone. In addition, IL1b
decreased the TGFb1-induced upregulation of LOX, which was
verified by means of measuring total lysyl oxidase activity levels in
the culture medium. Lysyl oxidase is involved in the cross-linking
of collagen, making the collagen network more resistant towards
proteolytic enzymes. Lowering lysyl oxidase activity levels has anti-
fibrotic effects [58,59].
The mechanisms of IL1b to attenuate the TGFb1-induced
myofibroblast formation are largely unknown. However, recent
studies regarding the mechanism of fibroblast to myofibroblast
transition has led to a renewed interest in the non-canonical
activation of the sonic Hedgehog (SHH) pathway, especially with
Figure 11. Effects of IL1b and TGFb1 on the expression level of matrix metalloproteinases in dermal and lung fibroblasts. HDFa and
HLFa were treated with IL1b, TGFb1, or a combination of both, for 24 and 48 h. (A–H) The mRNA levels of MMP1,22,29 and 14 were measured with
qRT-PCR and expressed as fold change compared to untreated control.
doi:10.1371/journal.pone.0091559.g011
Figure 12. Post-treatment effects of IL1b on TGFb1-stimulated dermal and lung fibroblasts on the expression level of matrix
metalloproteinases. Fibroblasts were pre-treated with TGFb1 for 48 h followed by IL1b for 48 h and quantified by qRT-PCR and expressed as fold
change compared to untreated control. (A–B) The mRNA levels of MMP1 in HDFa and HLFa. (C–D) The mRNA levels of MMP9 in HDFa and HLFa.
doi:10.1371/journal.pone.0091559.g012
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respect to the transcription factor GLI1 [11,12,14]. It has been
shown that the SHH pathway is activated in fibrotic conditions
[60,61,62], that GLI1 expression is induced by TGFb1, and the
transformation of fibroblasts into myofibroblasts is GLI1-depen-
dent [14,43]. In our study we also observed an upregulation of
GLI1 by TGFb1, but this was reduced by the addition of IL1b,
and as a consequence myofibroblast formation was hampered. A
similar effect was seen for the isoform of GLI1, GLI1DN.
Although our study showed that regulation of GLI1DN was
similar to GLI1, the function of GLI1DN needs to be further
investigated. The ability of IL1b to downregulate GLI1 could
potentially be anti-fibrotic, as GLI activation was found to be
required for TGFb1-induced myofibroblast differentiation [14].
Inhibition of GLI by GANT61 (i.e. directly blocking the binding of
GLI1 and GLI2 to their DNA targets) abrogated the effect of
TGFb1 on protein levels of aSMA and collagen type I in human
lung fibroblasts [14]. As with fibroblasts, activation of the SHH
pathway results in the transdifferentiation of hepatic stellate cells
into myofibroblasts, a key mechanism in liver fibrosis
[63,64,65,66]. Pharmacological inhibition of the SHH pathway
results in an attenuation of fibrosis in a variety of in vivo models,
namely unilateral ureteral obstruction (UUO) [67], systemic
sclerosis [68] and liver cirrhosis [66,69,70], although others did
not report improvements [71,72].
Another potential anti-fibrotic feature of IL1b might be its
ability to upregulate COL3A1. In all cases, stimulation with IL1b
resulted in an increased collagen type III to collagen type I ratio,
as expression of collagen type I went down and that of collagen
type III went up or remained the same. Interestingly, an increased
collagen III:I ratio is often found in situations where a scarless
healing is observed [73]. A prerequisite is that the produced
collagens are adequately modified. As stimulation with IL1b did
not result in a decrease in the expression level of prolyl
hydroxylase or lysyl hydroxylase, this seems to be the case.
A negative finding of our study was the steep increase in
PLOD2 expression when IL1b is added to TGFb1. Increased
levels of PLOD2 are seen in fibrotic conditions [49,50], resulting
in the formation of increased levels of pyridinium cross-links at the
expense of other cross-links, and making the collagen more difficult
to degrade. However, this might be compensated with IL1b by (1)
inhibiting the TGFb1-induced upregulation of LOX (resulting in
less lysyl oxidase activity levels, which likely results in a decrease in
the total amount of cross-links), and (2) by upregulating the
expression of various MMPs, which likely results in a higher
collagenolytic potential.
Our data might have major implications regarding the possible
use of IL1b inhibitors in fibrosis. We showed that IL1b is able to
suppress the pro-fibrotic features of TGFb1, and thus shows
potential anti-fibrotic properties, at least in the later stages of tissue
repair, where TGFb levels are more prominent. It is possible that
inhibition of IL1b in the early stages of tissue repair alone has
better effects than continuous suppression of IL1b activity during
the entire repair process. Inhibiting the early inflammatory
cascade certainly has an anti-fibrotic effect, but inhibiting IL1b
at the later phases of the healing response might have a negative
effect on the direct anti-fibrotic properties of IL1b on fibroblasts in
the presence of TGFb. In this context it is of interest, that a single
injection of an IL1b inhibitor immediately after ligation in a non-
reperfused infarction model attenuated the collagen accumulation
in the infarcted area [74], indicating that the timing and duration
of intervention with regard to IL1b is a key determinant of
outcome [75].Another relevant finding from our study is that
fibroblasts from different origins (in our case lung and skin) do not
always behave identical towards IL1b. Most marked in this respect
is the magnitude of COL1A1 suppression by IL1b between dermal
and lung fibroblasts after the pre-treatment with TGFb1, and the
magnitude of upregulation of COL3A1 and MMP1 by IL1b after
the pre-treatment with TGFb1. This difference in behaviour
between dermal and lung fibroblasts is in line with the observation
(albeit widely neglected) that fibroblasts derived from different
organs show major differences in phenotypic properties, as
reflected by huge differences in gene expression patterns [37,38].
These phenotypical differences should be taken into account in the
search for anti-fibrotic agents: an inhibitor may not have the
desired effect in all organ systems due to the different response of
the fibroblasts.
In conclusion we have shown that IL1b counteracts a central
process in fibrogenesis, namely the TGFb1-mediated transition of
fibroblasts into myofibroblasts. Clearly, the role of IL1b in fibrosis
should be reconsidered. Furthermore, we have shown that
fibroblasts from different origin (i.e. lung and dermal fibroblasts)
show different phenotypical responses towards IL1b. Both these
findings should be taken into consideration in the development of
future anti-fibrotic therapies. In the future we aim to investigate
what the underlying mechanism of IL1b is to the actions of
TGFb1-induced pro-fibrotic responses in fibroblasts with respect
to myofibroblast differentiation and collagen biosynthesis.
Supporting Information
Figure S1 Dose-dependent effects of TGFb1 and IL1b on
the genes expression level of pro-fibrotic markers in
dermal and lung fibroblasts. HDFa and HLFa were treated
with TGFb1 (0.5 and 2 ng/ml), IL1b (10 ng/ml), a combination
thereof, or both, for 48 hours (A–F). The mRNA levels of ACTA2,
GLI1 and COL1A1 were quantified with qRT-PCR and
expressed as a fold change compare to untreated control. Gene
expression data was normalized to the reference gene YWHAZ.
Data are represented as mean 6 SEM of quadruplicate
experiments.
(TIF)
Figure S2 Concentration-dependent effects of TGFb1
and IL1b on the gene expression level of the collagen-
modifying and -degrading enzymes in dermal and lung
fibroblasts. HDFa and HLFa were treated with TGFb1 (0.5
and 2 ng/ml), IL1b (10 ng/ml), a combination thereof, or both,
for 48 hours (A–F). The mRNA levels of PLOD2, MMP1 and
MMP9 were quantified with qRT-PCR and expressed as a fold
change compare to untreated control. Gene expression data was
normalized to the reference gene YWHAZ. Data are represented
as mean 6 SEM of quadruplicate experiments.
(TIF)
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